News | January 12, 2026
Aragen slashes drug development time with CHOMax platform
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Subscribe To Our Newsletter & Stay Updated
